Xenon Pharmaceuticals (XENE) Non-Current Assets (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Non-Current Assets data on file, last reported at $280.2 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $280.2 million, up 57.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $654.4 million (down 2.73% YoY), and the FY2025 annual result was $72.5 million, down 55.48% from the prior year.
• Non-Current Assets climbed to $280.2 million in Q1 2026 per XENE's latest filing, from $72.5 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $319.8 million in Q4 2023 and troughed at $12.4 million in Q1 2022.
• A 5-year average of $154.8 million and a median of $155.9 million in 2024 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets jumped 1475.28% in 2022, then slumped 55.48% in 2025.
• A 5-year view of Non-Current Assets shows it stood at $153.8 million in 2022, then jumped by 107.89% to $319.8 million in 2023, then sank by 49.08% to $162.9 million in 2024, then sank by 55.48% to $72.5 million in 2025, then soared by 286.38% to $280.2 million in 2026.
• Business Quant data shows XENE's Non-Current Assets at $280.2 million in Q1 2026, $72.5 million in Q4 2025, and $127.7 million in Q3 2025.